BE studies for cytotoxic drugs [Design Issues]

posted by Dr_Dan  – Germany, 2010-03-12 11:51 (5951 d 14:49 ago) – Posting: # 4903
Views: 3,832

Dear kadarusuresh

❝ 1. Study to be conducted on healthy volunteers or patients.

Cytotoxic drug => patients!

❝ 2. What type of study to be conducted like fasting, fed or steady state.

Depends on the drug. In general, a bioequivalence study should be conducted under fasting conditions as this is considered to be the most sensitive condition to detect a potential difference between formulations. For products where the SmPC recommends intake of the reference medicinal product on an empty stomach or irrespective of food intake, the bioequivalence study should hence be conducted under fasting conditions. For products where the SmPC recommends intake of the reference medicinal product only in fed state, the bioequivalence study should generally be conducted under fed conditions.

❝ 3. what is the right approach for the BE study for EU and US markets.

I suggest in case of BE studies in patients a scientific advice meeting with the regulatory authorities

Hope this helps
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
351 visitors (0 registered, 351 guests [including 19 identified bots]).
Forum time: 03:41 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5